source
- Oxford biotech OMass Therapeutics secures $310 million to advance genetic adrenal disorder programOxford-based OMass Therapeutics announced a $310 million private financing round, one of the largest recent fundraises for a UK biotech. The capital will fund the development of therapies targetin…
- Zealand Pharma signs up to $1.3 billion AI partnership with Generate Biomedicines for protein-based obesity drugsZealand Pharma announced a partnership with Generate Biomedicines to develop new protein-based treatments targeting obesity and related metabolic conditions. The collaboration will use Generate's…